Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors
JCO Precision Oncology · 2025
DOI: 10.1200/po-24-00925 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Amane Jubashi und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is a standard treatment for locally advanced gastric/gastroesophageal junction cancer (GC/GEJC). The impact of biomarker status on the efficacy of perioperative FLOT remains unclear. This study evaluated the association between clinicopathological features, including biomarker status, and the efficacy of perioperative FLOT in patients with resectable GC/GEJC. PATIENTS AND METHODS A retrospective observational study was conducted by reviewing medical records of patients treated with perioperative FLOT between February 2020 and March 2024. Eligible patients had histologically confirmed adenocarcinoma, resectable disease at stages cT2-4a and/or N0-3, M0, and underwent biomarker testing. RESULTS Among 116 eligible patients, human epidermal growth factor receptor 2 (HER2) positivity was observed in 7.8%, whereas PD-L1 combined positive score (CPS) of ≥1, ≥5, and ≥10 was detected in 90.5%, 44.0%, and 15.5% of patients, respectively. Claudin-18 isoform 2 (CLDN18.2) positivity (2+/3+ in ≥75% of tumor cells) was observed in 30.2% of patients. Major pathological response (MPR) and pathological complete response (pCR) rates were 22.4% (95% CI, 15.3 to 31.0) and 8.6% (95% CI, 4.2 to 15.3), respectively. Diffuse-type histology was a negative indicator for pathological response. CLDN18.2 expression decreased significantly after preoperative FLOT, with the median H-score declining from 285.0 to 187.5 ( P < .001) in patients with CLDN18.2 positivity at initiation. Maintained CLDN18.2 positivity was more frequently observed in patients without MPR compared with those with MPR (53.8% v 12.5%, P = .05). CONCLUSION HER2, PD-L1, and CLDN18.2 statuses were not linked to pathological response to FLOT in resectable GC/GEJC. CLDN18.2 expression significantly decreased after preoperative FLOT but remained higher in patients without MPR, suggesting that CLDN18.2-targeted therapy may warrant investigation in the perioperative setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
- Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
- Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
ORCID-Profile: Amane Jubashi, Izuma Nakayama, Shogo Takei, Yuki Matsubara, Yu Miyashita, Seiya Sato, Kazumasa Yamamoto, Akihito Kawazoe, Tadayoshi Hashimoto, Yoshiaki Nakamura, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Takayuki Yoshino, Masahiro Yura, Takahiro Kinoshita, Kohei Shitara
Zitieren
APA
Jubashi, A., Nakayama, I., Sakamoto, N., Takei, S., Matsubara, Y., Miyashita, Y., Sato, S., Ushiyama, S., Kobayashi, A., Okazaki, U., Okemoto, D., Yamamoto, K., Mishima, S., Kotani, D., Kawazoe, A., Hashimoto, T., Nakamura, Y., Kuboki, Y., Bando, H., …, & Shitara, K. (2025). Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors. JCO Precision Oncology. https://doi.org/10.1200/po-24-00925
Vancouver
Jubashi A, Nakayama I, Sakamoto N, Takei S, Matsubara Y, Miyashita Y, et al. Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors. JCO Precision Oncology. 2025. doi:10.1200/po-24-00925
BibTeX
@article{Jubashi2025,
author = {Jubashi, Amane and Nakayama, Izuma and Sakamoto, Naoya and Takei, Shogo and Matsubara, Yuki and Miyashita, Yu and Sato, Seiya and Ushiyama, Shinpei and Kobayashi, Akinori and Okazaki, Ukyo and Okemoto, Dai and Yamamoto, Kazumasa and Mishima, Saori and Kotani, Daisuke and Kawazoe, Akihito and Hashimoto, Tadayoshi and Nakamura, Yoshiaki and Kuboki, Yasutoshi and Bando, Hideaki and Kojima, Takashi and Yoshino, Takayuki and Kuwata, Takeshi and Sato, Kazuma and Fujita, Takeo and Yoshida, Mitsumasa and Yura, Masahiro and Kinoshita, Takahiro and Shitara, Kohei},
title = {Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-24-00925}
}
EUVIMED